This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ajay Anand, MD; Namrata Anand, MD
Boston, Mass

Arch Intern Med. 1995;155(6):641-642.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The article by Gucalp and colleagues,¹ comparing rapid and slow intravenous infusion regimens of pamidronate in the treatment of malignancy-associated hypercalcemia, was interesting and informative. In this context, I would like to draw the authors' attention to some further data concerning this subject.

The authors took into account several laboratory parameters in the randomized groups of patients receiving either a 4- or 24-hour infusion of 60 mg of pamidronate. Two other parameters have, however, also been shown to affect the response of tumor-induced hypercalcemia to pamidronate. Gurney and associates² showed that the concentration of parathyroid hormone-related protein is an important predictor of this response. An undetectable level of parathyroid hormone-related protein (<2 pmol/L) was associated with normalization of the serum calcium concentration in seven of seven patients, and the levels of 2 to 12 pmol/L were associated with a similar response in 10 of 14 patients, while the . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?